Abstract:Mohammed A Bazuhair, 1, 2 Mohammed Alsieni, 1 Hani Abdullah, 3 Jawahir A Mokhtar, 3– 5 Dalya Attallah, 4 Turki S Abujamel, 5, 6 Khalil K Alkuwaity, 5, 6 Hanouf A Niyazi, 3 Hatoon A Niyazi, 3 Hind AbdulMajed, 3 Noha Juma, 3 Mohammed W Al-Rabia, 3 Abdelbagi Alfadil, 2, 3 Karem Ibrahem 3 1 Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 2 Centre of Research Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia; 3 Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 4 Department of Clinical Microbiology Laboratory, King Abdulaziz University Hospital, Jeddah, 21589, Saudi Arabia; 5 Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, 21589, Saudi Arabia; 6 Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, 21589, Saudi Arabia Correspondence: Karem Ibrahem, Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, P.O. Box 80205, Jeddah, 21589, Saudi Arabia, Tel +966 562525685, Email Introduction: Candida is the primary cause of invasive fungal disease, candidiasis, especially in developed nations. The increasing resistance observed in multiple antibiotics, coupled with the prolonged process of creating new antibiotics from the ground up, emphasizes the urgent requirement for innovative methods and new compounds to combat Candida infections. Employing a treatment strategy that combines antibiotics can improve efficacy, broaden the spectrum of targeted fungal, and reduce the chances of resistance emergence. This approach shows potential in tackling the escalating problem of antibiotic resistance. The objective of this research is to explore the potential synergistic effects of combining 3-hydrazinoquinoxaline-2-thiol and thymoquinone against a variety of Candida isolates. This investigation aims to offer an understanding of the collective antimicrobial action of these compounds. Methods: Broth microdilution was utilized to assess the Minimum Inhibitory Concentrations (MICs) of 3-hydrazinoquinoxaline-2-thiol and thymoquinone for 22 clinical Candida isolates. Following this, a checkerboard assay was employed to analyze the interaction between 3-hydrazinoquinoxaline-2-thiol and thymoquinone, with a specific focus on the Fractional Inhibitory Concentration Index (FICI). Results: The MICs of thymoquinone and 3-hydrazinoquinoxaline-2-thiol were determined for 22 clinical Candida strains, with thymoquinone exhibiting MICs ranging from 64 to 8 μg/mL, and 3-hydrazinoquinoxaline-2-thiol displaying MICs varying from 64 to 8 μg/mL. Notably, the combination of 3-hydrazinoquinoxaline-2-thiol and thymoquinone resulted in a synergistic effect, leading to a significant reduction in MICs, with reductions of up to 64-fold with FICI below 0.5 against tested strains. Conclusion: The prospect of using 3-hydrazinoquinoxaline-2-thiol in combination with thymoquinone as an effective solution against Candida looks encouraging. Nevertheless, to validate its practical applicability, additional comprehensive testing and experiments are imperative. Keywords: Candida spp, antimicrobial resistance, 3-hydrazinoquinoxaline-2-thiol, thymoquinone, MIC, FICI Fungi have become significant contributors to human diseases, particularly affecting the immunocompromised and individuals hospitalized with severe underlying conditions. The associated morbidity and mortality are considerable, highlighting the emergence of fungal diseases as crucial public health concerns. 1–3 Analyzing the patterns of Infectious disease mortality rates US, revealed a notable rise in mortality rate attributed to mycoses. Most of these mycosis deaths were linked to infections caused by Aspergillus, Cryptococcus and Candida species. 2 Fungal pathogens contribute to a minimum of Thirteen million infections and one and a half million fatalities worldwide annually, predominantly affecting individuals with compromised immune function. 4 Earlier records indicate that fungal infections led to almost seventy five thousand hospitalizations and an additional almost nine million outpatient visits in 2014. This resulted in healthcare costs of at least $7 billion. 5 Presently, the clinical use of antifungals is co -Abstract Truncated-

Synthetic Naphthofuranquinone Derivatives Are Effective in Eliminating Drug-Resistant Candida albicans in Hyphal, Biofilm, and Intracellular Forms: An Application for Skin-Infection Treatment

Novel Potentially Antifungal Hybrids of 5-Flucytosine and Fluconazole: Design, Synthesis and Bioactive Evaluation.

ASLdC3: A Derivative of Acidic Sophorolipid Disrupts Mitochondrial Function, Induces ROS Generation, and Inhibits Biofilm Formation in Candida albicans

Discovery of novel purinylthiazolylethanone derivatives as anti-Candida albicans agents through possible multifaceted mechanisms

Novel Keto-Alkyl-Pyridinium Antifungal Molecules Active in Models of In Vivo Candida albicans Vascular Catheter Infection and Ex Vivo Candida auris Skin Colonization

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Alizarin and Chrysazin Inhibit Biofilm and Hyphal Formation by Candida albicans

Antifungal evaluation of quinoline-chalcone derivatives combined with FLC against drug-resistant Candida albicans.

Inhibition of apoptosis and biofilm formation in Candida auris by click-synthesized triazole-bridged quinoline derivatives

Fangchinoline inhibits growth and biofilm of Candida albicans by inducing ROS overproduction

Combined Application of Tacrolimus with Cyproconazole, Hymexazol and Novel {2-(3-R-1 H-1,2,4-triazol-5-yl)phenyl}amines as Antifungals: In Vitro Growth Inhibition and In Silico Molecular Docking Analysis to Fungal Chitin Deacetylase

Specific Antidermatophytic Activity of Trifluoromethylthiolated Cinnamate Derivatives: A New Approach to the Therapy of Superficial Fungal Infections of the Skin

Antifungal activity of Cinnamaldehyde derivatives against fluconazole-resistant Candida albicans

Design, Synthesis, and In Vitro and In Vivo Antifungal Activity of Novel Triazoles Containing Phenylethynyl Pyrazole Side Chains

Antifungal activity of the repurposed drug disulfiram against Cryptococcus neoformans

Antifungal Activity of 3-Hydrazinoquinoxaline-2-Thiol, a Novel Quinoxaline Derivative against Candida Species

Combination of fluconazole with natural compounds: A promising strategy to manage resistant Candida albicans infections

Antifungal potential, mechanism of action, and toxicity of 1,4-naphthoquinone derivatives

Thymoquinone Antifungal Activity against Candida glabrata Oral Isolates from Patients in Intensive Care Units-An In Vitro Study

The Combination of 3-Hydrazinoquinoxaline-2-Thiol with Thymoquinone Demonstrates Synergistic Activity Against Different Candida Strains

New Quinoline Derivatives and their Antimicrobial Potential Against Candida Albicans and Staphylococcus Aureus